Bladder Cancer Coverage from Every Angle

Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

Posted: Wednesday, September 27, 2017

Daniel P. Petrylak, MD, of Yale Cancer Center, discusses phase III study findings on docetaxel with or without ramucirumab in platinum-refractory advanced or metastatic urothelial carcinoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.